{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:32:37Z","timestamp":1787319157569,"version":"build-2736575974"},"reference-count":35,"publisher":"BMJ","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2012,3,30]]},"published-print":{"date-parts":[[2012]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study was aimed to evaluate the efficacy and tolerability of bisoprolol, in Indian patients diagnosed with stage I essential hypertension as first-line drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This was an open-label, phase IV, multicentric prospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings<\/jats:title>\n                    <jats:p>239 outpatient centres across India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>After ethical approval, patients who were willing to sign informed consent, who are newly diagnosed with JNC VII stage I essential hypertension (systolic blood pressure 140\u2013159\u2005mm\u2002Hg or diastolic blood pressure 90\u201399\u2005mm\u2002Hg) and who are prescribed bisoprolol were enrolled in the study. Patients with significant organ disease or complications, women of childbearing age refusing reliable contraceptive method, patients with known contraindications (like symptomatic bradycardia, significant atrioventricular blockade, sick sinus syndrome) and patients with known hypersensitivity reactions to bisoprolol and unwilling patients were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcomes measures<\/jats:title>\n                    <jats:p>The primary outcome measure was percentage of patients achieving blood pressure (BP) \u2264140\/90\u2005mm\u2002Hg at the end of 12\u2005weeks, while multiple secondary outcome measures were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 2418 patients screened, 2161 patients were recruited (66.64% men, mean age 51.7\u00b19.8\u2005years, smokers 19.19%) and 2131 (96.44%) patients achieved BP control. There was significant reduction in systolic blood pressure (\u221225.29; SD: 13.22\u2005mm\u2002Hg), diastolic blood pressure (\u221214.14; SD: 7.67\u2005mm\u2002Hg) and heart rate (\u221212\/min; SD: 6.15) compared with baseline (all p values &lt;0.05). The median dose of bisoprolol and average period required for the response were 5\u2005mg\/day and 33\u2005days, respectively. Bisoprolol was found to be well tolerated in the patients up to 10\u2005mg\/day. A total of 1.9% patients showed adverse events, which were mild to moderate in severity without any severe adverse event. None required treatment withdrawal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Bisoprolol is an effective and safe option to control BP. Thus, it can be used as one of the first-line antihypertensive in Indian patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2011-000683","type":"journal-article","created":{"date-parts":[[2012,5,15]],"date-time":"2012-05-15T01:10:06Z","timestamp":1337044206000},"page":"e000683","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and tolerability of a \u03b2-1 selective \u03b2 blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study"],"prefix":"10.1136","volume":"2","author":[{"given":"V","family":"Channaraya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R K","family":"Marya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Somasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashish","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K D","family":"Tibrewala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2012,5,14]]},"reference":[{"key":"2024051503233408000_2.3.e000683.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69252-0"},{"key":"2024051503233408000_2.3.e000683.2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200018010-00002"},{"key":"2024051503233408000_2.3.e000683.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa003417"},{"key":"2024051503233408000_2.3.e000683.4","doi-asserted-by":"publisher","DOI":"10.1161\/hc4601.099487"},{"key":"2024051503233408000_2.3.e000683.5","first-page":"141","article-title":"Hypertension \u2013 Pathogenesis and Pathophysiology","volume":"2","author":"Vikrant","year":"2001","journal-title":"Indian Acad Clin Med"},{"key":"2024051503233408000_2.3.e000683.6","first-page":"450","article-title":"Meta-analysis of prevalence of hypertension in India","volume":"49","author":"Gupta","year":"1997","journal-title":"Indian Heart J"},{"key":"2024051503233408000_2.3.e000683.7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001633"},{"key":"2024051503233408000_2.3.e000683.8","first-page":"326","article-title":"Prevalence, awareness and control of hypertension in Chennai\u2013The Chennai Urban Rural epidemiology study (CURES-52)","volume":"55","author":"Mohan","year":"2007","journal-title":"J Assoc Physicians India"},{"key":"2024051503233408000_2.3.e000683.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07492-2"},{"key":"2024051503233408000_2.3.e000683.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304013281303"},{"key":"2024051503233408000_2.3.e000683.11","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90181-N"},{"key":"2024051503233408000_2.3.e000683.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540330061036"},{"key":"2024051503233408000_2.3.e000683.13","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328333146d"},{"issue":"Suppl 11","key":"2024051503233408000_2.3.e000683.14","first-page":"S122","article-title":"Double blind comparison of cardioselective beta blockers in bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter study (BIMS)","volume":"8","author":"Buhler","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"key":"2024051503233408000_2.3.e000683.15","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000075790.33892.AE"},{"key":"2024051503233408000_2.3.e000683.16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1185\/03007995.2011.562884","article-title":"The role of beta blockers in the management of hypertension: an Asian perspective","volume":"27","author":"Tomlinson","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"2024051503233408000_2.3.e000683.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.307.6896.107"},{"key":"2024051503233408000_2.3.e000683.18","first-page":"575","article-title":"Report of the Canadian hypertension Society consensus Conference: 3. Pharmacologic treatment of essential hypertension","volume":"149","author":"Ogilvie","year":"1993","journal-title":"CMAJ"},{"key":"2024051503233408000_2.3.e000683.19","first-page":"730","article-title":"Treatment of hypertension: postmarketing surveillance study results of telmisartan monotherapy, fixed dose combination of telmisartan + hydrochlorothiazide\/amlodipine","volume":"107","author":"Arif","year":"2009","journal-title":"J Indian Med Assoc"},{"key":"2024051503233408000_2.3.e000683.20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/106002809502900412","article-title":"Bisoprolol: is this just another beta-blocker for hypertension or angina?","volume":"29","author":"Johns","year":"1995","journal-title":"Ann Pharmacother"},{"key":"2024051503233408000_2.3.e000683.21","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198608003-00002"},{"key":"2024051503233408000_2.3.e000683.22","first-page":"200","article-title":"Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol","volume":"36","author":"Harting","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"2024051503233408000_2.3.e000683.23","doi-asserted-by":"publisher","DOI":"10.1007\/BF00498849"},{"key":"2024051503233408000_2.3.e000683.24","first-page":"197","article-title":"Studies on the receptor profile of bisoprolol","volume":"36","author":"Klockow","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"2024051503233408000_2.3.e000683.25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/01.RES.49.2.326","article-title":"Characterization of [3H](+\/-)carazolol binding to beta-adrenergic receptors. Application to study of beta-adrenergic receptor subtypes in canine ventricular myocardium and lung","volume":"49","author":"Manalan","year":"1981","journal-title":"Circ Res"},{"key":"2024051503233408000_2.3.e000683.26","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/00005344-198411000-00024","article-title":"Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs","volume":"6","author":"Schliep","year":"1984","journal-title":"J Cardiovasc Pharmacol"},{"key":"2024051503233408000_2.3.e000683.27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0014-2999(86)90666-7","article-title":"Antagonistic effects of bisoprolol on several beta-adrenoceptor-mediated actions in anaesthetized cats","volume":"123","author":"Schliep","year":"1986","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 11","key":"2024051503233408000_2.3.e000683.28","first-page":"S36","article-title":"Affinity and selectivity of beta-adrenoceptor antagonists in vitro","volume":"8","author":"Wellstein","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 11","key":"2024051503233408000_2.3.e000683.29","first-page":"S96","article-title":"Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics","volume":"8","author":"Janka","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 5)","key":"2024051503233408000_2.3.e000683.30","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/00005344-199006165-00013","article-title":"Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment","volume":"16","author":"Fogari","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 11","key":"2024051503233408000_2.3.e000683.31","first-page":"S134","article-title":"Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cholesterol in patients with essential hypertension","volume":"8","author":"Frithz","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"key":"2024051503233408000_2.3.e000683.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7404.1427"},{"key":"2024051503233408000_2.3.e000683.33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4103\/0253-7613.83117","article-title":"Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension","volume":"43","author":"Badar","year":"2011","journal-title":"Indian J Pharmacol"},{"key":"2024051503233408000_2.3.e000683.34","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199904000-00004"},{"key":"2024051503233408000_2.3.e000683.35","doi-asserted-by":"publisher","DOI":"10.1007\/BF00609961"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2011-000683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T09:43:21Z","timestamp":1715766201000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2011-000683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,5,14]]},"published-print":{"date-parts":[[2012]]}},"alternative-id":["10.1136\/bmjopen-2011-000683"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2011-000683","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}